Atossa Therapeutics, Inc. - נכסים נקיים למניה בודדת ATOS

Supply chain optimization for raw materials, combined with patent protection for breast cancer therapies, guarantees Atossa Therapeutics (ATOS) stable revenue and a moat against competitors. This chart of current share prices, where the indicator stands at 2.70, confirms the business's resilience. Meanwhile, Atossa Therapeutics (ATOS) strictly adheres to ESG standards by implementing energy-efficient technologies and safe waste recycling within its biolabs.

For the biotechnology brand Atossa Therapeutics (ATOS), which focuses on breast oncology, this indicator reflects the actual net asset value minus liabilities on a per-share basis. By analyzing the current book value per share, an investor assesses the business's intrinsic capitalization, which confirms the company's financial stability during the implementation of its long-term scientific strategy.